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Abstract OBJECTIVE: Lifelong steroid therapy and exposure to adrenal androgen excess 
in 21-hydroxylase deficient (21-OHD) congenital adrenal hyperplasia (CAH) 
children and adolescents may modify circadian blood pressure profile and result 
in vascular complications. The objective of the study was to evaluate vascular 
abnormalities in 21-OHD children and adolescents in relation to their genotypes. 
DESIGN: A cross-sectional study conducted at a tertiary referral center.
Patients: Seventy patients with 21-OHD CAH (27 boys), aged from 3 to 17.9 
years: 9 with nonclassic CAH, 61 with classic CAH: 10 with simple virilising (SV) 
and 51 with salt wasting CAH (13-Del/Del, 8-Del/I2G, 7-I2G/I2G and 23-other 
genotypes). 
MAIN OUTCOMES MEASURES: The assessment of systolic and diastolic BP (SBP, 
DBP) loads, night dip% and arterial ambulatory stiffness index (AASI) in 21-OHD 
CAH patients. 
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RESULTS: The highest percentage of abnormal SBP 
loads was found in SW CAH patients with Del/Del 
genotype and DBP loads in SV CAH patients. The 
lowest percentage of abnormal SBP and DBP loads was 
found in NC CAH and in SW CAH I2G/I2G subgroup. 
Abnormal values of night time dip% and the highest 
values of AASI were found in Del/Del and Del/I2G. 
Girls were more affected than boys in relation to abnor-
mal ABPM profiles. ABPM parameters were associated 
with cortisol values. AASI correlated positively with 
free androgen index.
CONCLUSION: Pediatric patients with CAH present 
vascular abnormalities related to the steroid therapy 
and androgen excess and pronounced more in certain 
subgroups of CAH (SV and SW: Del/Del, Del/I2G). 
 
Abbreviations:
ABPM - Ambulatory Blood Pressure Monitoring
AASI - Ambulatory Arterial Stiffness Index
BP - Blood Pressure
CAH - Congenital Adrenal Hyperplasia
24 h SBP load - 24 hour mean systolic BP load
24 h DBP load - 24 hour mean diastolic BP load
dDBP - mean day-time diastolic BP 
dSBP - mean day-time systolic BP
nDBP - mean night-time diastolic BP 
nSBP - mean night-time systolic BP
FAI - free androgen index
TST - testosterone
SHBG - sex hormone binding globulin
FM% - fat mass%
LTM% - lean tissue mass%
TBW% - total body water%
FC - Fludrocortisone
HC - Hydrocortisone
INTRODUCTION
Lifelong steroid therapy and exposure to adrenal 
androgen excess in 21-hydroxylase deficient (21-OHD) 
congenital adrenal hyperplasia (CAH) children and 
adolescents may result in vascular complications (Fal-
hammar et al. 2015). 
In 21-OHD CAH a deficit in corticosteroids leads to 
an increase in ACTH synthesis and stimulation of the 
adrenal cortex. The accumulation of precursors above 
the block shunted subsequently to the adrenal sex hor-
mone pathway exposes patients to androgen excess. 
There is a classic form comprising the salt wasting 
variant (SW) manifested neonatally by severe salt loss 
and virilisation of external genitalia in females and the 
simple virilizing variant (SV) where salt loss is mild or 
absent and manifested by GnRH-independent preco-
cious puberty (Merke & Bornstein 2005). The nonclassic 
(NC) variant is usually diagnosed with hyperandrogen-
ism later in childhood or adolescence (Merke & Born-
stein 2005). The goal of therapy is a replacement of 
steroids (glucocorticoids and mineralocorticoids) to 
prevent adrenal crisis and suppression of the abnormal 
secretion of adrenal androgens (Speiser et al. 2010). 
Vascular profiles of 21OHD patients on lifelong steroid 
therapy depend on the balance between steroid under- 
or overtreatment (Harrington et al. 2012; Wojcik et al. 
2013; Subbarayan et al. 2014). Glucocorticoids, often 
given in supraphysiological doses may lead to hyperten-
sion (Bachelot et al. 2007). The most severe type of CAH 
is associated with more intensive steroid treatment, and 
that may be a secondary cause of hypertension and 
later cardiovascular problems. Longstanding under-
treatment with elevation of adrenal androgens may also 
increase vascular mortality (Maggio & Basaria 2009). 
CAH children often have disrupted circadian cor-
tisol rhythm and in consequence blood pressure (BP) 
rhythms, factors that may have important long-term 
health implications (Volkl et al. 2006; Wojcik et al. 
2013). An abnormal BP circadian rhythm, and in par-
ticular a non-dipping phenomenon is associated with 
increased cardiovascular risks including left ventricular 
hypertrophy (Fumo et al. 1992; Sihm et al. 1995; Ver-
decchia et al. 1995), cerebrovascular (Kario et al. 1996) 
and cardiovascular morbidity (Verdecchia et al. 1995), 
kidney damage (Timio et al. 1995) and increased mor-
tality (Ohkubo et al. 1997; Ohkubo et al. 2002; Wojcik 
et al. 2013). 
The ambulatory arterial stiffnes index (AASI) is an 
indirect arterial stiffness measure, which can be derived 
from 24 hr ambulatory blood pressure monitoring 
(ABPM) and has been proven to be independently asso-
ciated with cardiovascular adverse events, especially 
stroke (Xu et al. 2011; Kollias et al. 2012; Wojcik et al. 
2015; Verbakel et al. 2016). In recent work Falhammar 
et al. (2015) analysing 588 CAH patients (>80% with 
known CYP21A2 mutations) from the national swed-
ish population-based registers for the first time showed 
that in CAH population not only risk factors for car-
diovascular disorders but also cardiovascular diseases 
were increased: hypertension, atrial fibrillation, venous 
thromboembolism and stroke.
There is a good phenotype-to-genotype correlation 
in 21OHD CAH and it seems that genotyping may be 
useful in predicting vascular risks in 21-OHD CAH 
patients (Falhammar et al. 2007; Hagenfeldt et al. 2008; 
Nordenskjold et al. 2008; Falhammar et al. 2009; Frisen 
et al. 2009; New et al. 2013; Falhammar et al. 2015). 
The objective of the study was to evaluate circadian 
blood pressure profiles and ambulatory arterial stiffness 
index in 21OHD children and adolescents in relation to 
their genotypes. 
SUBJECTS AND METHODS
Subjects
Seventy patients with 21-OHD CAH (27 boys), aged 
from 3 to 17.9 years: 9 with nonclassic CAH, 61 with 
classic CAH: 10 with simple virilising (SV) and 51 with 
salt wasting CAH (13-Del/Del, 8-Del/I2G, 7-I2G/I2G 
and 23-other genotypes). The patients were not diag-
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nosed by newborn screening as it was unavailable at 
the time of the study. SW CAH patients were diagnosed 
in the neonatal period. SV patients were diagnosed 
at around 3±1 years of age and NC CAH patients at 
around 7±2 years of age. In all patients CAH was diag-
nosed in steroid urine profile. The diagnosis of 21OHD 
was confirmed by genotype in 56 patients. With regard 
to the remaining 14 cases all patients were diagnosed 
clinically with salt wasting CAH in the neonatal period 
and 21OHD was confirmed in steroid urine profile. 
Patients with nonclassic form were receiving only 
hydrocortisone (HC) (mean dose 11.9±3.5 mg/m2, 
tid) and all classic CAH patients received glucocorti-
coid replacement therapy with hydrocortisone (mean 
dose 17.2±4.2 mg/m2 in SW CAH and 19.5±2.5 mg/m2 
in SV CAH,tid) and mineralocorticoid therapy with 
fludrocortisone (FC) (66.5±36.5 mcg/m2 in SW CAH 
and 28.6±15.5 mg/m2 in SV CAH, bid). The adequacy 
of therapy was monitored periodically on the basis of 
clinical and laboratory data, in accordance with current 
guidelines (Speiser et al. 2010). None of the patients 
used additional medication. 
This study was conducted in accordance with the 
guidelines in The Declaration of Helsinki and was 
approved by the local ethical committee. All partici-
pants gave their informed consent.
Clinical study
Body weight and height were measured to the near-
est 0.1 kg and 0.1 cm, respectively, using a stadiometer 
(Harpenden, UK) and a balanced scale. As the standard 
of reference normal values from the local population 
were used (Palczewska & Niedzwiedzka 2001). 
Assays
Plasma cortisol, testosterone (TST) and sex hormone 
binding globulin (SHBG) were assessed by chemi-
luminescence immunoassay (Centaur-Bayer). Free 
androgen index (FAI) was calculated with the use of 
a formula: FAI=TST (nmol/l) × 100 /SHBG (nmol/l), 
the FAI norm is <5. Serum concentrations of upright 
aldosterone, plasma renin activity and 17-OHP were 
measured by RIA. Cortisol was assessed in plasma 2 
hours after 1st, 2nd and 3rd dose of hydrocortisone. 24 
hour collection of urine was used for the assessment 
of free cortisol in urine. The area under the curve was 
calculated with the use of formula:



n
i
iii bahA
1
)(
2
1
Bioimpedance analysis
Electrical bioimpedance analysis (BIA) was performed 
in patients using Nutriguard Data Input device with 
Bianostic electrodes (Fresenius BCM, Data Input, Ger-
many). Following parameters were calculated: total 
body water (TBW%), lean tissue mass (LTM%) and fat 
mass (FM %).
ABPM assessment
24-hour BP monitoring was performed using an Ambu-
latory BP Monitor (Spacelabs 90217, USA) with meth-
odology described by our group previously (Wojcik 
et al. 2013). The following parameters were analyzed: 
systolic and diastolic mean, day and night loads (24h 
SBP load%, dSBP, nSBP, 24hDBP load%, dDBP, nDBP), 
nocturnal dipping (nighttime dip%) and ambulatory 
arterial stiffness index (AASI). BP load was defined as 
the percentage of valid ambulatory BP measurements 
above a set threshold (95th percentile for sex and the 
height) value (Wühl et al. 2002; National High Blood 
Pressure Education Program Working Group 2004). 
Loads in excess of 30% were considered elevated. 
The calculation of nocturnal dipping was based on a 
formula by the American Heart Association: [(dSBP–
nSBP)/dSBP] × 100. Normal dipping was defined as 
a ≥10% decline in BP (de Silva et al. 2004). AASI was 
derived from ABPM using a previously described for-
mula (Kollias et al. 2012).
Statistical analysis
In order to compare the two groups the two-sided 
Mann-Whitney U-test and ANOVA tests were used. 
Spearman ρ was used to measure the strength of asso-
ciation between pairs of variables. The level of signifi-
cance was set at p<0.05. Calculations were performed 
using the STATISTICA 10.0 PL soft ware (Poland).
RESULTS
Circadian blood pressure profiles in relation to geno-
types are presented in Table 1. There were no significant 
differences in relation to age and BMI SDS between the 
subgroups of patients.
The highest HC doses were used in SV CAH and the 
lowest in NC CAH. The highest FC doses were used 
in SW Del/Del group and the lowest in SV CAH. In 
children with NC CAH we were not using FC. In SW 
CAH group the lowest doses of HC and FC were used 
in I2G/I2G subgroup. 
Levels of plasma renin activity and aldosterone were 
related to CAH phenotype.
Studied CAH patients did not have an overt hyper-
tension. 24hr SBP loads and day SBP loads were higher 
in Del/Del than in other subgroups. Night SBP load was 
higher in Del/Del and Del/I2G than in other genotypes. 
The lowest 24 hr SBP loads as well as day and night SBP 
loads were found in NC and I2G/I2G subgroups. 
24 hr DBP, day DBP and night DBP loads were 
higher in SV CAH and lower in I2G/I2G, Del/I2G and 
NC CAH when compared to other groups.
AASI was higher in Del/Del and Del/I2G and lower 
in NC CAH when compared to other subgroups. 
Abnormal night time dip was found in 57% of 
patients (data not shown). This parameter differed 
significantly between Del/Del and Del/I2G vs I2G/I2G 
(6.0±1.6 and 6.9±4.4 vs 12.4±5.2%).
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Tab. 1. Circadian blood pressure profiles in CAH patients depending on genotype. Data are expressed as mean [SD]. 
CAH NC SV
SW
p-value
Del/Del Del/I2G I2G/I2G Other Total
N 9 10 13 8 7 23 51
Age years 8.7[4.1] 11.7 [4.7] 8.2[4.2] 8.7[4.1] 6.7[3.2] 9.5[4.5] 8.7[4.9] NS
BMI SDS 0.45
[1.1]
0.37
[1.1]
0.4
[1.3]
0.5
[1.4]
0.7
[1.1]
0.8
[2.1]
0.6
[1.6]
NS
Hydrocortisone 
daily dose (mg/m2)
11.9
[3.5]abcfg
19.5
[2.5]ae
16.6
[3.7]c
18.9
[5.2]b
15.6
[5.1]e
17.1
[3.9]f
17.2
[4.2]g
<0.05
Fludrocortisone 
daily dose (mcg/m2)
0 28.6
[15.5]adefg
79
[45.1]a
65.9
[30.2]d
64.5
[43.1]e
64.1
[31.9]f
66.5
[36.5]g
<0.05
PRA (ng/ml/h)
[n:1.5-5.7]
2.1
[0.7]bg
2.7
[2.3]a
6.8
[5.2]abef
3.1
[1.1]
4.1
[1.7]e
3.5
[2.1]f
4.3
[2.1]g
<0.05
Aldosteron
(pg/ml)
[n:35-310]
169.6
[75.5]
177.9
[45.1]adef
87.1
[52.1]a
89.8
[45.1]d
94.1
[30.1]e
108.0
[88.7]f
96.6
[22.3]
<0.05
24h SBP load % 6.8
[8.5]bfg
16.8
[14.9]a
28.1
[15.5]abcd
13.3
[7.7]d
6.7
[5.2]c
20.4
[8.5]f
19.1
[21.2]g
<0.05
dSBP load % 4.6
[1.1]bfg
14.4
[13.5]
22.7
[11.1]bde
8.8
[5.5]d
8.2
[5.7]e
18.6
[20.8]f
16.5
[5.5]g
<0.05
nSBP load % 14.8
[8.8]b*
25.9
[12.2]a
38.6
[44.7]c*
30.4
[15.2]d
0
[0.0]abdce
23.5
[15.5]e
26.0
[10.1]
<0.05
24h DBP load % 6.9
[7.3]acfg
16.3
[9.7]ad
14.5
[13.1]c
6.9
[5.5]d*
8.1
[6.3]
14.8
[5.8]f*
12.3
[5.5]g
<0.05
dDBP load % 3.5
[2.1]afg
13.7
[5.5]ad
10.2
[5.6]
5.3
[2.2]d*
7.0
[3.2]
13.5
[5.6]f*
10.2
[5.3]g
<0.05
nDBP load (%) 18.7
[5.4]
27.3
[15.5]ae
25.4
[19.2]
13.9
[2.8]a
12.6
[8.6]e
20.0
[9.9]
19.4
[4.6]
<0.05
AASI 0.309
[0.1]bcg
0.337
[0.1]a
0.41
[0.1]b
0.47
[0.2]acef
0.339
[0.1]e
0.37
[0.1]f
0.399
[0.2]g
<0.05
Nighttime dip% 8.6
[3.8]
8.9
[4.1]
6.0
[1.6]c
6.9
[4.4]d
12.4
[5.2]cdf
8.2
[4.9]f
7.7
[2.5]
<0.05
TBW% 55.1
[5.7]
53.9
[4.7]a
56.9
[6.1]
57.2
[5.0]a
55.4
[4.8]
54.4
[5.5]
55.8
[4.9]
<0.05
Symbols [a–g] present significant differences between two subgroups (the same letter). Legend: NC – non classic CAH, SV – simple virilising 
CAH, SW – salt wasting CAH, PRA – plasma renin activity.
TBW% was higher in Del/Del (not significantly) and 
Del/I2G and lower in SV CAH.
Daily cortisol profiles are presented in Table 2. The 
highest values of cortisol area under the curve and 24 hr 
urine cortisol were observed in SV CAH and the lowest 
in NC CAH and SW I2G/I2G.
Analysis of cortisol profiles revealed that morn-
ing levels of cortisol assessed 2 hours after the first 
dose of hydrocortisone were within the normal range 
[50–230 ng/ml]. In SV CAH group morning levels of 
cortisol were close to upper normal range. Later during 
the day we were able to reach a reduction of cortisol but 
we were unable to reach a good evening drop of corti-
sol mimicking a normal cortisol daily rhythm. The best 
cortisol profiles with lowest values of evening cortisol 
were reached in NC CAH group and also in I2G/I2G 
subgroup.
The highest level of FM% and lowest LTM% were 
found in SV CAH and opposite results were found in 
Del/I2G SW CAH. 
The highest levels of TST and FAI and the lowest 
levels of SHBG were found in SV CAH. Opposite 
results were found in I2G/I2G subgroup. 17OHP values 
did not differ between the subgroups (data not shown).
Circadian blood pressure and cortisol profiles in 
CAH patients depending on gender are presented in 
Table 3. In all CAH forms females were presenting 
higher SBP loads than males (significance only in SW 
CAH group). DBP loads were higher in females than in 
males in NC and SV groups and night DBP load also in 
SW group (tendencies). AASI was higher and night dip 
was lower in females than males in NC (tendency) and 
SW groups. There were no differences in HC, FC, PRA, 
Aldosteron, cortisol metabolism parameters between 
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the sexes apart from cortisol values after the 1st dose 
higher in SW CAH females. Testosterone, FAI and 
TBW% were higher in females than males in SW group.
Circadian blood pressure profiles in relation to bone 
age are presented in Table 4. There were no significant 
differences in age and BMI between groups with/with-
out advanced bone age.
24 hr, day and night SBP loads% were significantly 
higher in patients with advanced bone age. There was 
a gender difference seen in SBP loads: 24 hr,day and 
night SBP were higher in females than males (signifi-
cance in a group with advanced bone age). There were 
no differences in 24 hr DBP loads and day DBP loads 
between the groups. Significantly higher night DBP 
load was found in females with advanced bone age. 
Night dip% did not differ between the groups,but 
females within both groups had night dipping lower than 
males. Females without advanced bone age had night 
dipping lower than females with advanced bone age.
AASI was higher in patients with advanced bone 
age. In males with advanced bone age AASI was signifi-
cantly higher than in males without advanced bone age. 
There were no gender differences in AASI in a group 
with advanced bone age. AASI was higher in females 
than males in the group without advanced bone age. 
Daily cortisol profiles in relation to bone age are pre-
sented in Table 5. There were no significant differences 
in cortisole profiles,17OHP and HC dose between 
groups with /without advanced bone age.
Cortisol in 24 hr urine collection, TST level and FM % 
were significantly higher and LTM%, TBW% and FC dose 
significantly lower in a group with advanced bone age.
In females without advanced bone age FC dose, 
TBW%, LTM% were higher and FM% lower than in 
females with advanced bone age. Lower cortisol area 
under the curve,cortisol in urine and more optimal cor-
tisol profiles were found in females without advanced 
bone age than in females with advanced bone age. In 
both groups cortisol values in plasma and urine were 
lower in females than in males. There were no gender 
differences in relation to TST levels within both groups.
DISCUSSION
In the present study we aimed to assess for the first 
time the genotype-vascular correlations in our cohort 
of 21-hydroxylase deficient pediatric patients. 
Studied CAH patients did not have an overt hyper-
tension on a 3–4-monthly routine out-patient visits 
however 24-hour ABPM revealed a tendency to abnor-
Tab. 2. Cortisol daily profiles in CAH patients depending on genotype. Data are expressed as mean [SD]. 
CAH NC SV
SW
p-value
Del/del Del/I2G I2G/I2G other Total
N 9 10 13 8 7 23 51
cortisol area under the 
curve 
382.1
[110.6]a
566.8
[157.2]acdefg
442.1
[138.2]c
429.4
[92.5]d
371.4
[118.6]e
415.7
[102.6]f
419.6
[103.4]g
<0.05
24hr urine cortisol
(mcg/volume)
56.3
[44.5]a
161.8
[76.1] acdefg
64.4
[54.1]c
98.6
[54.2]d
54.2
[29.8]e
76.1
[64]f
74.1
[65]g
<0.05
Cortisol
2 hrs after 1st HC dose 
(ng/ml)
139.2
[72.6]a
219.5
[110.1]aefg
178.7
[71.7]c
178.5
[71.9]
140.9
[38.0]e
140.5
[51.6]fc
156.6
[61.4]g
<0.05
Cortisol 
2 hrs after 2nd HC dose 
(ng/ml)
120.1
[71.9]a
172.9
[62.3]acdefg
135.8
[51.8]c
128.9
[34.5]d
118.2
[60.1]e
125.6
[38.2]f
128.1
[43.6]g
<0.05
Cortisol
2 hrs after 3rd HC dose 
(ng/ml)
78.
[45.9]ab*
162.7
[56.6]acdefg
124.3
[59.4]cb
127.2
[37.9]d*
105.8
[59.5]e
128.5
[55.5]f
124.8
[53.3]g
<0.05
LTM% 70.0
[9.8]
68.9
[8.9]a
72.4
[11.1]
73.8
[7.1]a
69.9
[9.3]
69
[8.9]
71.1
[8.9]
<0.05
FM% 22.4
[8.4]
23.8
[6.8]a
20.1
[8.8]
19.3
[6.7]a
22.1
[6.6]
23.3
[7.9]
21.4
[6.5]
<0.05
TST
(ng/ml)
0.4
[0.3]af
1.7
[1.2]aecdg
0.6
[0.1]c
0.6
[0.2]d
0.1
[0.1]e
1.3
[0.2]f
0.9
[0.2]g
<0.05
SHBG
(nmol/l)
99.4
[10.4]
45.6
[5.4]ade
94.5[9.8] 109.0
[12.2]d
112.6
[12.5]e
77.8
[8.9]
93.9
[12.1]a
<0.05
FAI 2.29
[1.1]a
29.1
[5.4]acdefg
3.1
[1.1]c
3.2
[1.2]d
0.5
[0.0]e
7.1
[1.2]f
4.5
[1.0]g
<0.05
Symbols [a–g] present significant differences between two subgroups (the same letter). Legend: NC – non classic CAH, SV – simple virilising 
CAH, SW – salt wasting CAH.
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mal SBP and DBP loads mostly at nighttime and in 
more than 50% of patients abnormal night time dip. 
Interestingly we have found a positive correlation 
between all assessed parameters of 24h ABPM and cor-
tisol level after the 3rd dose of HC. The highest per-
centage of abnormal SBP loads was found in SW CAH 
patients with Del/Del genotype and DBP loads in SV 
CAH patients. The lowest percentage of abnormal SBP 
and DBP loads was found in NC CAH and in I2G/I2G 
SW subgroup and in these two groups cortisol profiles, 
cortisol in urine and area under the curve were better 
mimicking the physiology. NC CAH patients were not 
receiving FC and in I2G/I2G FC and HC dose were 
lower than in other SW subgroups (a tendency). Del/
Del patients were receiving the highest FC dose when 
compared to other subgroups, however the mean PRA 
was above the upper normal range.According to the 
current guidelines (Speiser et al. 2010) we were trying to 
avoid suppressing plasma renin activity below the lower 
normal range with FC.
AASI was highest in Del/Del and Del/I2G genotypes 
and lowest in NC CAH. AASI correlated with cortisol 
in urine, cortisol area under the curve and cortisol after 
the 1st dose of HC. The lowest night time dipping was 
found in Del/Del and Del/I2G and the highest in I2G/
I2G. The meaning of abnormal ABPM results in Del/
Tab. 3. Circadian blood pressure and cortisol profiles in CAH patients depending on gender. Data are expressed as mean [SD].
CAH
NC SV SW
p-value
M F M F M F
N 4 5 5 5 20 15
Age years 8.1[2.8] 8.5[4.3] 12.1[5.7] 11.2[3.9] 6.7[4.0] 7.1[5.2] Ns
HC mg/m2 11.3
[2.9]
12.8
[3.9]
20.7
[2.8]
18.3
[1.9]
17.7
[3.4]
16.7
[4.8]
Ns
FC mcg/m2 0 0 29.5
[35.5]
27.8
[30.6]
74.4
[41.9]
61.8
[29.1]
Ns
Cortisol area under the 
curve 
413.9
[155.2]
358.1
[81.4]
669.1
[172.9]
485.1
[90.8]
439.9
[116.2]
403.0
[105.4]
Ns
Cortisol
2 hrs after 1st HC dose 
(ng/ml)
176.4
[107.5]
111.2
[20.7]
270.8
[131.3]
168.2
[59.3]
191.8
[58.4]*
142.9
[61.7]*
<0.05
Cortisol 
2 hrs after 2nd HC dose 
(ng/ml)
80.8
[13.1]
149.2
[86.7]
199.7
[60.3]
146.2
[57.6]
122.7
[45.0]
137.2
[42.3]
Ns
Cortisol
2 hrs after 3rd HC dose 
(ng/ml)
100.9
[10.0]
61.2
[57.0]
181.5
[75.0]
147.7
[39.3]
134.9
[54.7]
116.6
[51.9]
Ns
PRA
(ng/ml/h)
1.7[1.0] 2.1[0.9] 1.45[1.1] 3.9[2.6] 4.6[2.3] 3.1[1.2] Ns
Aldosteron
(pg/ml)
170.3
[13.3]
169
[173.9]
213.8
[270.0]
141.9
[112.0]
117.2
[120.7]
82.2
[92.6]
Ns
24h SBP load % 1.8[3.1] 10.5[9.7] 9.7[11.5] 23.9[15.5] 11.5[11.6]* 24.9[24.7]* <0.05
dSBP load % 0.9[1.6] 7.4[7.9] 9.2[12.2] 19.5[14.0] 10.5[10.9]* 21.2[25.1]* <0.05
nSBP load % 3.5[6.1] 23.3[27.7] 13.3[13.1] 38.5[29.2] 16.8[21.4]* 33.2[32.2]* <0.05
24h DBP load % 6.9[10.9] 6.9[5.2] 10.7[8.6] 21.8[7.8] 13.6[15.5] 11.6[10.4] Ns
dDBP load % 3.2[4.3] 3.7[5.4] 8.5[7.8] 18.7[8.7] 13.6[15.7] 11.6[7.8] Ns
nDBP load % 14.0[24.0] 22.2[20.9] 21.7[13.9] 32.8[16.5] 18.4[22.9] 20.0[23.5] Ns
AASI 0.21[0.1] 0.38[0.1] 0.35[0.1] 0.32[0.1] 0.38[0.1]* 0.42[0.2]* <0.05
Nighttime dip% 11.8[3.0] 6.1[1.9] 8.9[2.4] 9.1[5.6] 10.0[4.2]* 6.01[8.9]* <0.05
TST (ng/ml) 0.2[0.1] 0.5[0.3] 2.4[2.1] 0.7[0.5] 0.7[0.7]* 1.04[0.7]* <0.05
FAI 0.6[0.4] 5.7[1.2] 41.9[28.3] 3.4[0.1] 4.4[5.6]* 4.6[4.2]* <0.05
TBW% 58.5[7.5] 52.9[4.4] 55.1[4.6] 51.9[5.03] 54.4[5.7]* 57.4[3.8]* <0.05
Symbol [*] presents significant differences between two subgroups. Legend: NC – non classic CAH, SV – simple virilising CAH, SW – salt 
wasting CAH
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Del and Del/I2G children is not known. According to 
Falhammar et al. (2015) even if SBP and DBP loads are 
higher in severe phenotypes as was also observed in 
presented study it is speculated that due to lower epi-
nephrine production in SW Del/Del and I2G pheno-
type the risk for further cardiovascular events might be 
smaller than in milder phenotypes. 
The prevalence of hypertension varies widely between 
studies. Some report systolic and diastolic hypertension 
(Roche et al. 2003;Merke & Bornstein,2005;Finkielstain 
et al. 2012;Amr et al. 2014;Subbarayan et al. 2014). 
Others in the paediatric CAH patients with normal 
weight even showed diastolic hypotension (Volkl et al. 
2006). Ubertini et al. (2009) found that systolic and dia-
stolic BP was normal in CAH patients. This might be due 
to the use of lower doses of fludrocortisone compared 
with our study (mean dose 48 vs 74.8 mcg/m2) as well.
Comparisons between the three CAH forms revealed 
that the SV CAH form (in 50% with I172N genotype) 
was the one most negatively affected in relation to met-
abolic parameters like increased TST, FAI, low SHBG, 
low lean muscle mass, high fat mass, decreased TBW% 
and increased diastolic pressure. It is in contrast to Sub-
barayan et al. (2014) who did not find significant dif-
ference in the prevalence of hypertension between SV 
and SW groups. Interestingly, we have found that in our 
study the mean glucocorticoid doses in SV CAH were 
higher than in SW and NC CAH groups. This is due 
to the goal of the therapy in this subgroup: to decrease 
hyperandrogenemia causing GnRH-independent pre-
cocious puberty. Unfavourable cortisol daily profile, 
area under the curve and cortisol in urine indicate that 
the doses of corticosteroids used in SV CAH form were 
too high considering the milder form of disease due to a 
higher activity of 21-hydroxylase than in SW subgroups 
(Falhammar et al. 2015). We could also speculate that 
the compliance might be better in precocious puberty 
in CAH but it certainly needs further research. As 
mean time for diagnosis in SV CAH was around 3 years 
of age probably prolonged androgen excess might also 
contribute to adverse metabolic effects. In SW patients 
Del/Del and Del/I2G subgroups were most negatively 
affected in relation to SBP loads, AASI and night time 
dipping what is related to higher FC doses and TBW% 
than in other subgroups. 
Although these were mostly tendencies, they con-
firmed different metabolic profiles with a tendency to 
overtreatment and increase in fat mass in SV CAH and 
undertreatment with a tendency to salt wasting and 
increased lean tissue mass in SW CAH (especially Del/
Del and Del/I2G). 
The most favourable outcome in relation to metabo-
lism and vascular assessments was found in NC CAH 
and I2G/I2G SW subgroup. The mean glucocorticoid 
Tab. 4. Circadian blood pressure profiles in CAH patients in relation to bone age. Data are expressed as mean [SD]. 
Bone age advanced
N=34
Bone age not advanced
N=35
p-value
M
n=12
F
N=16
Total
M
N=14
F
N=12
Total
Age years 8.5[4.2] 10.8[4.0] 9.6[4.2] 7.8[4.7] 10.1[5.5] 8.3[5.1] n.s.
Bone age 
years
10.8[4.1] 12.7[4.2]b 11.7[4.1]c 6.8[4.6]b 9.3[5.5] 7.6[5.1]c <0.05
BMI SDS 0.8[1.4] 0.7[0.8] 0.4[1.3] 0.07[1.2] 0.06[1.4] 0.7[1.8] n.s.
AASI 0.4[0.1]a 0.4[0.1] 0.38[0.1]c 0.3[0.2]da 0.4[0.2]d 0.37[0.2]c <0.05
24 h SBP 
load%
10.9[10.0]a 22.3[20.7]ad 20.4[5.5]c 9.3[5.5]d 17.84[7.4] 13.4[7.1]c <0.05
dSBP load% 10.5[11.6]a 22.3[24.5]abe 17.6[20.9]c 8.2[10.3]b 13.8[19.0]e 10.9[15.1]c <0.05
nSBP load% 12.4[4.8]ae 36.8[30.4]adb 27.2[27.7]c 16.2[22.2]d 25.4[30.2]eb 20.6[26.3]c <0.05
24 h DBP 
load%
10.7[4.5] 13.7[3.2] 13.1[3.7] 12.3[3.2] 9.7[9.5] 11.7[4.2] n.s.
dDBP load% 10.1[13.8] 10.7[8.4] 10.5[10.6] 11.6[14.2] 6.9[8.8] 9.4[11.9] n.s.
nDBP load% 13.5[18.8]ad 23.7[22.7]a 19.7[21.5] 22.3[22.3]d 16.8[16.9] 19.6[19.7] <0.05
Night dip % 10.7[4.5]a 8.3[4.5]b 9.2[4.6] 9.4[3.3]d 4.5[10.9]abd 7.0[8.2] <0.05
PRA (ng/ml/h)
[n:1.5-5.7]
3.0[4.1]a 2.9[3.5]b 2.9[3.7] 5.4[7.5]abe 2.9[3.5]e 4.2[5.9] n.s.
Aldosteron
(pg/ml)
[n:35-310]
186.2
[197.9]ad
124.8
[127.7]b
148.1
[157.5]
108.3
[100.7]d
71.0
[75.1]ab
88.9
[88.6]
<0.05
Symbols [a,b,d,e] present significant differences between two subgroups with the same letter. Legend: PRA – plasma renin activity.
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doses were lowest compared to other subgroups and 
subsequently cortisol daily profile, cortisol area under 
the curve and cortisol in urine were mimicking better 
the physiology. Additionaly NC CAH were not treated 
with FC and presented lower androgen levels. This is 
in contrast to study by Williams et al. (2010) where 
NC-CAH boys and girls had higher systolic blood pres-
sure compared with controls, in contrast to classic CAH 
boys and girls. In I2G/I2G SW subgroup FC dose was 
lower than in other SW subgroups. If it means that I2G/
I2G SW patients may have more favourable metabolic 
profile needs further studies. As presented by New et al. 
(2013) although in most cases I2G mutation in intron 2 
is associated with the SW phenotype as it was in all our 
I2G/I2G patients diagnosed in neonatal period with salt 
wasting phenotype, some patients present with the SV 
form (New et al. 2013). It was observed that the I2G 
(g.655A/C>G) mutation activates a cryptic upstream 3’ 
splice acceptor site and causes aberrant splicing and its 
occasional association with the SV form is probably due 
to the correct splicing of a small number of transcripts 
(New et al. 2013). 
In our study the highest percentage of abnormal 
SBP loads was found in females in all groups (NC, SV 
and SW) and DBP in females in NC and SV group (sig-
nificance only in SW group). Additionaly females in 
NC and SW groups had higher AASI and lower night 
dipping levels than males (significance only in SW 
group). Interestingly, in Falhammar et al. (2015) study, 
adult females were generally more affected especially 
in SV (I172N) and the nonclassic group than males, 
and that supports our study. Additionally Falhammar 
et al. (2015) presented an increased risk of stroke in 
NC females and in our study there was a tendency to 
higher AASI in females than males in NC group. Kollias 
et. al. (2012) in a meta-analysis and systematic review 
presented evidence suggesting that AASI, an indirect 
parameter of arterial function, independently predicts 
future cardiovascular events, particularly stroke.
In our study there were no gender differences in 
HC, FC dosing and BMI between males and females. 
It could be speculated that longer androgen exposure 
can increase the vascular risk in females. 24 hr SBP load 
and night time SBP load were positively correlated with 
Tab. 5. Cortisol daily profiles in CAH patients in relation to bone age. Data are expressed as mean [SD]. Symbols [a,b,d,e] present significant 
differences between two subgroups with the same letter.
Bone age advanced
N=34
Bone age not advanced
N=35
p-value
M
n=12
F
N=16
Total
M
N=14
F
N=12
Total
Cortisol area under the 
curve 
482.2
[108.5]a
433.4
[92.5]b
451.5
[99.6]
467.6
[178.1]d
373.0
[112.8]abd
423.7
[156.2]
<0.05
24hr urine cortisol
(mcg/volume)
102.9
[72.3]a
87.2
[72.6]
93.4
[71.6]c
96.1
[153.8]
61.3
[65.2]a
78.7
[117.3]c
<0.05
Cortisol
2 hrs after 1st HC dose 
(ng/ml)
205.4
[52.9]ae
143.5
[47.4]ab
167.8
[57.6]
181.9
[105.9]b
151.7
[71.8]e
167.9
[91.3]
<0.05
Cortisol 
2 hrs after 2nd HC dose 
(ng/ml)
141.7
[60.8]
149.2
[51.9]b
146.3
[54.6]
126.0
[55.5]
117.3
[43.0]b
121.9
[49.4]
<0.05
Cortisol
2 hrs after 3rd HC dose 
(ng/ml)
125.8
[60.5]
114.8
[58.8]b
118.9
[58.5]
141.1
[57.4]bd
109.4
[4.2]d
127.0
[53.1]
<0.05
17OHP (ng/ml) 7.6[4.1] 8.01[3.5] 6.9[4.2] 5.7[5.1] 7.0[4.6] 6.4[5.0] n.s.
TST (ng/ml) 1.3[1.5] 0.9[0.7] 1.12[1.1]c 0.8[1.2] 0.6[0.5] 0.7[0.9]c <0.05
FAI 22.5[20.1]ab 6.32[4.3]b 13.7[5.4]c 8.6[4.5] 1.7[1.6]a 5.4[3.0]c <0.05
SHBG (nmol/l) 61.4
[49.4]
65.2
[43.3]
65.2
[43]c
102.7
[58.9]
103.5
[50.6]
100.7
[50.2]c
<0.05
HC dose
(mg/m2)
17.9[4.4] 17.3[5.5] 17.6[4.9] 16.5[3.6] 16.3[3.8] 16.4[3.7] n.s.
FC dose
(mcg/m2)
45.0[12.1]a 39.1[32]be 41.6[40.4]c 69.2[42.0]ab 59.9[36.3]e 66.4[38.1]c <0.05
LTM% 69.5[11.2]a 66.3[6.9]b 67.7[8.7]c 71.5[7.1]e 78.1[4.8]abe 73.7[6.9]c <0.05
FM% 22.8[9.4]a 25.3[5.4]b 24.2[7.2]c 21.5[6.1]e 15.9[3.7]abe 19.6[5.9]c <0.05
TBW% 54.9[5.2]a 53.1[5.2]b 53.6[5.2]c 55.4[4.6]e 59.6[4.2]abe 56.9[4.4]c <0.05
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TST and FAI levels, suggesting that higher nocturnal 
SBP could represent an early effect of androgen excess 
similarly to Ubertini et al. (2009) study, who found cor-
relation between mean DBP and nocturnal DBP and 
TST level.We found also an association between AASI 
as well as night dip% and FAI that could also confirm 
the negative influence of hyperandrogenism on arterial 
wall function especially in females.
In order to assess the effect of prolonged androgens 
excess on ABPM parameters we evaluated patients 
with and without advanced bone age. 24 hr SBP , day 
SBP and night SBP loads were significantly higher in 
patients with advanced bone age. There was a gender 
difference seen in SBP: 24 hr, day and night loads were 
higher in females than males (significance in a group 
with advanced bone age).
AASI was higher in patients with advanced bone 
age. In males with advanced bone age AASI was higher 
than in males without advanced bone age. Whether it 
means that androgen excess can increase cardiovascu-
lar risks (stroke) also in CAH males needs follow-up 
research. AASI was higher in females than males in the 
group without advanced bone age. 
In females without advanced bone age higher: FC 
dose, TBW%, LTM%, lower: FM%, cortisol area under 
the curve,cortisol in urine and more optimal cortisol 
profiles were found than in females with advanced 
bone age. In both groups cortisol values in plasma and 
urine were lower in females than in males. There were 
no gender differences in relation to TST within both 
groups.
To summarise it seems that females are more affected 
than males by prolonged androgens exposure in a 
group with advanced bone age. In the group without 
advanced bone age it seems that AASI and BP param-
eters are influenced by FC dose causing an increase in 
TBW%. We have found a correlation between FC dose 
and TBW%, as well as between TBW% and SBP and 
DBP loads.
This cross-sectional study presents some limitations. 
The most important one is small number of patients in 
CAH subgroups for ascertaining associations however 
some of them have been in accordance to other large 
studies in adults assessing genotype-metabolic correla-
tions (Falhammar et al. 2015). Another limitation is no 
control group. All comparisons were performed within 
the CAH subgroups.
CONCLUSION
In the examined group children and adolescents with 
CAH present vascular abnormalities related to the ste-
roid therapy and androgen excess pronounced more in 
certain subgroups of CAH (SV, SW: Del/Del and Del/
I2G) and in females. We have found a negative influ-
ence of androgens on BP parameters both in males and 
females. These single centre results might be encour-
aging to use genotyping in monitoring corticosteroid 
and FC dosing in pediatric CAH patients. Future larger 
multicenter studies are necessary to present genotype 
and metabolic correlations in children.
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Supplementary materials:
Correlations (all with p<0.05):
AASI correlates with SHBG (r:–0.4) , FAI (r:0.4), 17OHP (r:0.3), night SBP load (r:0.3), night dip (r:–0.5),HC dose (r:0.3), cortisol in urine (r:0.3), 
cortisol area under the curve (r:0.3), cortisol after the 1st dose of HC (r:0.4).
Night dip% correlates with FAI (r:–0.5).
24 hr SBP load% correlates with TST (r:0.3), SHBG(r:–0.4), FAI (r:0.4), cortisol 2h after 3rd dose of HC(r:0.3), TBW (r:0.4), LTM% (r:–0.4), FM% 
(r:0.4).
Day SBP load% correlates with cortisol 2h after 3rd dose (r:0.3), TBW (r:0.5), LTM% (r:–0.5), FM% (r:0,5).
Night SBP load% correlates with TST (r:0.3), SHBG(r:–0.3), FAI (r:+0.4), cortisol after the 3rd dose of HC (r:0.3), LTM% (r:–0.4).
24 DBP load% correlates with SHBG(r:–0.4), cortisol after the 3rd dose of HC(r:0.4), TBW (r:0.5), LTM% (r:–0.5), FM% (r:0.5).
Day DBP load% correlates with :cortisol area under the curve (r:0.3), cortisol after the 3rd dose of HC (r:0.5), TBW (r:0.5), LTM% (r:–0.5), FM% 
(r:0.5).
Night DBP load% correlates with SHBG (r:–0.4), cortisol after the 3rd dose of HC (r:0.3), TBW (r:–0.6),LTM% (r:–0.6), FM% (r:0.6).
FC dose correlates with TBW% (r:0.4, p<0.05).
